NASDAQ:GH

Guardant Health (GH) Stock Forecast, Price & News

$29.64

-0.42 (-1.40%)

(As of 09/29/2023 ET)

Compare

Today's Range: $28.47
▼
$30.66
50-Day Range: $25.80
▼
$39.97
52-Week Range: $20.67
▼
$62.75

Volume: 2.58 million shs
Average Volume: 1.92 million shs
Market Capitalization: $3.49 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $55.44

Guardant Health MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 87.0% Upside
$55.44 Price Target
Short Interest: Bearish
5.87% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.48
Upright™ Environmental Score
News Sentiment: 0.71
Based on 17 Articles This Week
Insider Trading: Selling Shares
$72,755 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($3.81) to ($3.33) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.70 out of 5 stars

Medical Sector

97th out of 973 stocks

Medical Laboratories Industry

4th out of 24 stocks

4.5

Analyst's Opinion

Consensus Rating
Guardant Health has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 15 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $55.44, Guardant Health has a forecasted upside of 87.0% from its current price of $29.64.
Amount of Analyst Coverage
Guardant Health has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.0

Short Interest

Percentage of Shares Shorted
5.87% of the outstanding shares of Guardant Health have been sold short.
Short Interest Ratio / Days to Cover
Guardant Health has a short interest ratio ("days to cover") of 4.5.
Change versus previous month
Short interest in Guardant Health has recently decreased by 1.43%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Guardant Health does not currently pay a dividend.
Dividend Growth
Guardant Health does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Guardant Health has received a 72.30% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Genomics analysis tools" and "Clinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Guardant Health is -0.48.

3.2

News and Social Media Coverage

News Sentiment
Guardant Health has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 17 news articles for Guardant Health this week, compared to 3 articles on an average week.
Search Interest
23 people have searched for GH on MarketBeat in the last 30 days. This is an increase of 64% compared to the previous 30 days.
MarketBeat Follows
7 people have added Guardant Health to their MarketBeat watchlist in the last 30 days. This is an increase of 250% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Guardant Health insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $72,755.00 in company stock.
Percentage Held by Insiders
Only 6.20% of the stock of Guardant Health is held by insiders.
Percentage Held by Institutions
92.65% of the stock of Guardant Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Guardant Health are expected to grow in the coming year, from ($3.81) to ($3.33) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Guardant Health is -6.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Guardant Health is -6.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Guardant Health has a P/B Ratio of 50.24. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Guardant Health (NASDAQ:GH) Stock

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360; Guardant360 LDT; Guardant360 CDx; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It also offers Shield Test; Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, a suite of advanced analytical technologies to enhance the performance and clinical utility of cancer tests. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. Guardant Health, Inc. has a research collaboration agreement with the Parker Institute for Cancer Immunotherapy to study the correlation between molecular cancer biomarkers and patient response to immunotherapy treatment across various types of cancer. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

GH Price History

30 days | 90 days | 365 days | Advanced Chart

GH Stock News Headlines

September 29, 2023 | finance.yahoo.com

Guardant Health (GH) Surges 8.8%: Is This an Indication of Further Gains?

September 29, 2023 | americanbankingnews.com

Guardant Health (NASDAQ:GH) Upgraded to "Overweight" at Piper Sandler

September 29, 2023 | Altimetry (Ad)

Seven millionaires secretly enable market shock?

A fraud expert to the FBI just shared a surprising new prediction. Own stocks? Watch it now.

September 28, 2023 | finance.yahoo.com

Why Guardant Health Stock Jumped 15% This Week

September 28, 2023 | finance.yahoo.com

Why Guardant Health Stock Popped Again Today

September 27, 2023 | msn.com

Guardant Health stock climbs following Piper Sandler upgrade

September 27, 2023 | msn.com

Piper Sandler Upgrades Guardant Health (GH)

September 27, 2023 | markets.businessinsider.com

Guardant Health Has 'Underlying Business Strength' Says This Bullish Analyst

September 29, 2023 | Altimetry (Ad)

Seven millionaires secretly enable market shock?

A fraud expert to the FBI just shared a surprising new prediction. Own stocks? Watch it now.

September 27, 2023 | finance.yahoo.com

Guardant Health (GH): A Potential Value Trap?

September 23, 2023 | americanbankingnews.com

Guardant Health, Inc. (NASDAQ:GH) Receives Consensus Rating of "Moderate Buy" from Analysts

September 22, 2023 | finance.yahoo.com

Guardant Health (GH): A Hidden Value Trap? Unpacking the Risks and Rewards

September 16, 2023 | finance.yahoo.com

Insider Buyers At Guardant Health Sitting On US$653k Profit

September 8, 2023 | markets.businessinsider.com

Bank of America Securities Keeps Their Buy Rating on Guardant Health (GH)

September 5, 2023 | markets.businessinsider.com

Guardant Health (GH) Receives a Buy from Craig-Hallum

September 1, 2023 | businesswire.com

Guardant Health to Participate in the Morgan Stanley 21 st Annual Global Healthcare Conference

August 31, 2023 | finance.yahoo.com

Guardant Health to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

August 9, 2023 | msn.com

Piper Sandler Maintains Guardant Health (GH) Neutral Recommendation

August 8, 2023 | finance.yahoo.com

Guardant Health Stock Sees Renewed Technical Strength

August 5, 2023 | finance.yahoo.com

Guardant Health, Inc. (NASDAQ:GH) Q2 2023 Earnings Call Transcript

August 4, 2023 | markets.businessinsider.com

The Latest Analyst Ratings for Guardant Health

August 4, 2023 | msn.com

Citigroup Maintains Guardant Health (GH) Buy Recommendation

August 3, 2023 | seekingalpha.com

Guardant Health Non-GAAP EPS of -$0.82 beats by $0.11, revenue of $137.2M beats by $7.78M

August 3, 2023 | seekingalpha.com

Guardant Health, Inc. 2023 Q2 - Results - Earnings Call Presentation

August 3, 2023 | finance.yahoo.com

Guardant Health Reports Second Quarter 2023 Financial Results and Increases Revenue Guidance

August 2, 2023 | benzinga.com

Preview: Guardant Health's Earnings

July 31, 2023 | markets.businessinsider.com

Craig-Hallum Sticks to Their Buy Rating for Guardant Health (GH)

See More Headlines

Receive GH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Guardant Health and its competitors with MarketBeat's FREE daily newsletter.

GH Company Calendar

Last Earnings: 8/03/2023
Today: 9/29/2023
Next Earnings (Estimated): 11/02/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Medical laboratories
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:GH
CUSIP: N/A
CIK: 1576280
Web: www.guardanthealth.com
Phone: (855) 698-8887
Fax: 888-974-4258
Employees: 1,793
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $55.44
High Stock Price Forecast: $88.00
Low Stock Price Forecast: $34.00
Forecasted Upside/Downside: +87.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 15 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($4.91)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-654,590,000.00
Net Margins: -99.62%
Pretax Margin: -99.34%
Return on Equity: -427.89%
Return on Assets: -30.51%

Debt

Debt-to-Equity Ratio: 3.89
Current Ratio: 6.96
Quick Ratio: 6.65

Sales & Book Value

Annual Sales: $449.54 million
Price / Sales: 7.74
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.59 per share
Price / Book: 50.12

Miscellaneous

Outstanding Shares: 117,690,000
Free Float: 110,395,000
Market Cap: $3.48 billion
Optionable: Not Optionable
Beta: 0.87

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Dr. Helmy Eltoukhy Ph.D. (Age 44)
Co-Founder, Co-CEO & Chairman
Comp: $11.63k

Dr. AmirAli Talasaz Ph.D. (Age 44)
Co-CEO & Director
Comp: $11.18k

Mr. Michael Bell (Age 54)
Chief Financial Officer
Comp: $630.99k

Mr. John G. Saia (Age 50)
Chief Legal Officer & Corp. Sec.
Comp: $627.18k

Dr. Craig Eagle M.D. (Age 56)
Chief Medical Officer
Comp: $649.13k

Mr. Christopher Freeman (Age 49)
Chief Commercial Officer
Comp: $630.39k

Ms. Ines Dahne-Steuber
Chief Operating Officer

Ms. Darya Chudova
Chief Technology Officer

Mr. Kumud Kalia (Age 57)
Chief Information Officer

Ms. Jennifer Higgins
VP of Public Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

GH Stock - Frequently Asked Questions

Should I buy or sell Guardant Health stock right now?: 15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Guardant Health in the last twelve months. There are currently 15 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" GH shares.
View GH analyst ratings or view top-rated stocks.
What is Guardant Health's stock price forecast for 2023?: 15 Wall Street analysts have issued 1-year target prices for Guardant Health's stock. Their GH share price forecasts range from $34.00 to $88.00. On average, they anticipate the company's stock price to reach $55.44 in the next year. This suggests a possible upside of 87.5% from the stock's current price.
View analysts price targets for GH or view top-rated stocks among Wall Street analysts.
How have GH shares performed in 2023?: Guardant Health's stock was trading at $27.20 on January 1st, 2023. Since then, GH shares have increased by 8.7% and is now trading at $29.57.
View the best growth stocks for 2023 here.
When is Guardant Health's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our GH earnings forecast.
How were Guardant Health's earnings last quarter?: Guardant Health, Inc. (NASDAQ:GH) issued its quarterly earnings data on Thursday, August, 3rd. The company reported ($0.67) EPS for the quarter, topping the consensus estimate of ($1.25) by $0.58. The business had revenue of $137.15 million for the quarter, compared to the consensus estimate of $129.44 million. Guardant Health had a negative trailing twelve-month return on equity of 427.89% and a negative net margin of 99.62%. The business's revenue for the quarter was up 25.7% compared to the same quarter last year. During the same period last year, the business earned ($2.25) earnings per share.
What ETFs hold Guardant Health's stock?: ETFs with the largest weight of Guardant Health (NASDAQ:GH) stock in their portfolio include SPDR S&P Health Care Services ETF (XHS), ROBO Global Healthcare Technology and Innovation ETF (HTEC), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), ARK Genomic Revolution ETF (ARKG), iShares U.S. Healthcare Providers ETF (IHF), Fidelity Disruptive Medicine ETF (FMED), Franklin Genomic Advancements ETF (HELX) and Invesco Nasdaq Biotechnology ETF (IBBQ).
What guidance has Guardant Health issued on next quarter's earnings?: Guardant Health updated its FY 2023 earnings guidance on Thursday, August, 3rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $545.00 million-$550.00 million, compared to the consensus revenue estimate of $541.39 million.
What is Helmy Eltoukhy's approval rating as Guardant Health's CEO?: 52 employees have rated Guardant Health Chief Executive Officer Helmy Eltoukhy on Glassdoor.com. Helmy Eltoukhy has an approval rating of 95% among the company's employees. This puts Helmy Eltoukhy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Guardant Health own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Guardant Health investors own include NVIDIA (NVDA), Trade Desk (TTD), Block (SQ), Alibaba Group (BABA), PayPal (PYPL), Shopify (SHOP), Okta (OKTA), Alteryx (AYX), Roku (ROKU) and Twilio (TWLO).
When did Guardant Health IPO?: (GH) raised $200 million in an initial public offering (IPO) on Thursday, October 4th 2018. The company issued 12,500,000 shares at $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Cowen, Leerink Partners and William Blair were co-managers.
What is Guardant Health's stock symbol?: Guardant Health trades on the NASDAQ under the ticker symbol "GH."
How do I buy shares of Guardant Health?: Shares of GH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Guardant Health's stock price today?: One share of GH stock can currently be purchased for approximately $29.57.
How much money does Guardant Health make?: Guardant Health (NASDAQ:GH) has a market capitalization of $3.48 billion and generates $449.54 million in revenue each year. The company earns $-654,590,000.00 in net income (profit) each year or ($4.91) on an earnings per share basis.
How many employees does Guardant Health have?: The company employs 1,793 workers across the globe.
How can I contact Guardant Health?: Guardant Health's mailing address is 505 PENOBSCOT DR., REDWOOD CITY CA, 94063. The official website for the company is www.guardanthealth.com. The company can be reached via phone at (855) 698-8887, via email at investors@guardanthealth.com, or via fax at 888-974-4258.

This page (NASDAQ:GH) was last updated on 9/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial